AAP
SRPT icon

Arax Advisory Partners’s Sarepta Therapeutics SRPT Stock Holding History

Arax Advisory Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Buy
11,692
+10,139
+653% +$192K ﹤0.01% 2221
2026
Q1 		$33.8K Buy
1,553
+1,446
+1,351% +$28K ﹤0.01% 1844
2025
Q4 		$2.3K Sell
107
-20,898
-99% -$440K ﹤0.01% 3207
2025
Q3 		$405K Buy
21,005
+20,945
+34,908% +$373K 0.01% 987
2025
Q2 		$1.28K Buy
60
+43
+253% +$1.83K ﹤0.01% 2702
2025
Q1 		$1.09K Sell
17
-34
-67% -$3.58K ﹤0.01% 2282
2024
Q4 		$6.2K Sell
51
-3
-6% -$368 ﹤0.01% 1668
2024
Q3 		$6.75K Buy
54
+2
+4% +$276 ﹤0.01% 1577
2024
Q2 		$8.22K Buy
52
+12
+30% +$1.54K ﹤0.01% 1367
2024
Q1 		$5.18K Buy
40
+23
+135% +$2.82K ﹤0.01% 894
2023
Q4 		$1.64K Sell
17
-50
-75% -$4.8K ﹤0.01% 1048
2023
Q3 		$8.12K Buy
67
+24
+56% +$2.71K ﹤0.01% 772
2023
Q2 		$4.92K Buy
43
+8
+23% +$1.03K ﹤0.01% 868
2023
Q1 		$4.83K Buy
35
+20
+133% +$2.59K ﹤0.01% 857
2022
Q4 		$1.94K Hold
15
– – ﹤0.01% 947
2022
Q3 		$2K Buy
+15
New +$1.51K ﹤0.01% 991
2022
Q1 		– Sell
-56
Closed -$5K – 1206
2021
Q4 		$5K Hold
56
– – ﹤0.01% 777
2021
Q3 		$5K Hold
56
– – ﹤0.01% 765
2021
Q2 		$4K Buy
+56
New +$4.25K ﹤0.01% 796

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Arax Advisory Partners's SRPT Position: Q2 2026 in Review

Arax Advisory Partners increased its Sarepta Therapeutics (SRPT) stake by 653% in Q2 2026, buying an estimated $192K and bringing the position to 11,692 shares worth $210K. The position accounts for ﹤0.01% of the portfolio, ranked #2221.

Arax Advisory Partners first reported a position in SRPT in Q2 2021 and has held it in 19 quarters since. The position peaked at $405K in Q3 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Arax Advisory Partners held 11,692 shares of Sarepta Therapeutics worth $210K as of Q2 2026.
  • Arax Advisory Partners bought 10,139 Sarepta Therapeutics shares in Q2 2026, an estimated $192K.
  • Sarepta Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2221 holding.
  • Arax Advisory Partners first reported a position in Sarepta Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Arax Advisory Partners's Sarepta Therapeutics position peaked at $405K in Q3 2025.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.